Fracture Healing Assessed by HR-pQCT After Administration of Calcium and Vitamin D

November 16, 2021 updated by: Joop P.W. van den Bergh, VieCuri Medical Centre

Assessment of Fracture Healing by High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) and Bone Strength Analysis in Standard Care and After Immediate Administration of Calcium and Vitamin D Supplementation

This study is designed as a single-blind RCT in 80 postmenopausal women to compare the effect of immediate administration of daily calcium supplementation (1000 mg calcium) or two daily dosages of calcium + vitamin D (1000 mg calcium + 880 IU vitamin D or 1000 mg calcium + 1760 IU vitamin D) to standard care (administration of vitamin D3 12 weeks after fracture) in terms of calculated bone strength based on analysis of cortical and trabecular bone parameters using HR-pQCT, fracture healing and functional outcome.

Study Overview

Study Type

Interventional

Enrollment (Actual)

52

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Limburg
      • Venlo, Limburg, Netherlands, 5912BL
        • Viecuri Medical Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Postmenopausal women older than 50 years who present themselves in clinic with a distal radius fracture due to a trauma.
  • Patients with a stable distal radius fracture treated by cast immobilization.
  • Patients who understand the conditions of the study and are willing and able to comply with the scheduled biochemical and radiographic evaluations and the prescribed rehabilitation.
  • Patients who signed the Ethics Committee approved specific Informed Consent Form prior to inclusion.

Exclusion Criteria:

  • Patients who underwent surgery of the wrist or radius on a previous occasion on the same side or who need surgery this time.
  • Patients with active or suspected infection such as pneumonia or complicated urinary tract infection in the last 3 months.
  • Patients with malignancy or a pathological fracture in the last 12 months.
  • Patients with a neuromuscular or neurosensory deficit, e.g. Parkinson's disease, which would limit the ability to assess the performance during the healing period.
  • Patients with known systemic or metabolic disorders leading to progressive bone deterioration, such as: hyperthyroidism, hyperparathyroidism, chronic kidney disease with eGFR<30 ml/min, sarcoidosis, hypercalcemia,
  • Patients with an active inflammatory disease during the last year such as rheumatoid arthritis, systemic lupus erythematous, inflammatory bowel disease, e.g. Crohn's disease and ulcerative colitis.
  • The use of glucocorticoids during the last 12 months.
  • Patients with an allergy to calcium, calcium carbonate, cholecalciferol, aspartame, citric-acid, lactose, dimethicone, methylcellulose, sorbic acid, macrogole, polyvidone, mannitol, orange flavour, natriumsaccharine, starch or sucrose.
  • Patients, who as judged by the principal Investigator, are mentally incompetent or are unlikely to be compliant with the follow-up evaluation schedule.
  • Patients with other severe concurrent joint involvements that can affect their outcome.
  • Patients who are already selected for another trial concerning distal radius fractures.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Standard care
Start of calcium and vitamin D3 supplementation according to standard care, i.e. 12 weeks after fracture.
Active Comparator: Calcium
Immediate administration of daily calcium supplementation (1000 mg calcium)
Immediate administration of daily calcium supplementation for 12 weeks
Other Names:
  • Cacit effervescent tablet '1000'
Active Comparator: Calcium and low dose vitamin D
Immediate administration of daily calcium + low dose vitamin D supplementation (1000 mg calcium + 880 IU vitamin D).
Immediate administration of daily calcium and low dose vitamin D (1 sachet CaD 1000/880) supplementation for 12 weeks
Other Names:
  • CaD® sachet 1000/880
Active Comparator: Calcium and high dose vitamin D
Immediate administration of daily calcium + high dose vitamin D supplementation (1000 mg calcium + 1760 IU vitamin D)
Immediate administration of daily calcium and high dose vitamin D (2 sachets CaD 500/880) supplementation for 12 weeks
Other Names:
  • CaD® sachets 500/880
No Intervention: Already on treatment with Calcium or vitamin D
Patients who are already treated with Calcium or Vitamin D.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bone strength
Time Frame: 1 year
Bone strength parameters will be assessed by HRpQCT
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fracture healing
Time Frame: 1 year
1 year
Functional outcome assessed by PRWE
Time Frame: 1 year
Functional outcome is assessed using Patient-Related Wrist Examination (PRWE) questionnaire
1 year
Functional outcome assessed by QuickDASH
Time Frame: 1 year
Functional outcome is assessed using QuickDASH questionnaires
1 year
Functional outcome assessed using VAS for pain score
Time Frame: 1 year
Functional outcome is assessed using VAS for pain score on Visual Analogue Scale (VAS)
1 year
Functional outcome assessed using range of motion
Time Frame: 1 year
Functional outcome is assessed by measuremt of range of motion of the fractured wrist
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: J PW van den Bergh, MD, PhD, Viecuri Medical Centre

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2014

Primary Completion (Actual)

June 18, 2020

Study Completion (Actual)

June 18, 2020

Study Registration Dates

First Submitted

September 26, 2014

First Submitted That Met QC Criteria

August 30, 2016

First Posted (Estimate)

September 5, 2016

Study Record Updates

Last Update Posted (Actual)

November 26, 2021

Last Update Submitted That Met QC Criteria

November 16, 2021

Last Verified

November 1, 2021

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bone Fracture

Clinical Trials on Calcium

Subscribe